🇺🇸 FDA
Pipeline program

Single dose intravenous injection of BBM 002

IIT2022019

Phase 1 gene_therapy active

Quick answer

Single dose intravenous injection of BBM 002 for Hemophilia A is a Phase 1 program (gene_therapy) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Hemophilia A
Phase
Phase 1
Modality
gene_therapy
Status
active

Clinical trials